Summary of Purpose
This is a randomized, placebo-controlled, subject- and investigator-blinded trial of BAF312 in intracerebral hemorrhage (ICH) patients to study efficacy, safety, and tolerability. BAF312 is a drug that could potentially limit brain inflammation after ICH, and thereby improve neurological outcome for hemorrhagic stroke patients. In this study, ICH patients meeting study criteria will be randomized at 1:1 ratio...Read More →
The following dates are available for this trial. Trial information last updated on 19 April 2018.
|24 Dec 2017||8 Nov 2017||17 Mar 2020||17 Mar 2020||1 Apr 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Novartis Pharmaceuticals